Bentiromide

CHEMBL1200368 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
404.4 g/mol
LogP
3.3
Phase
4

A peptide used as a diagnostic test for exocrine pancreatic function; after oral ingestion, pancreatic chymotrypsin cleaves the peptide to release para-aminobenzoic acid, which is measured in urine. It is not used as a therapeutic agent.

Molekularmasse

404,4000 g/mol

LogP

3,30

TPSA

116,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1

InChI

InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1

Molecular Formula

C23H20N2O5

HBD / HBA

4 / 5

Rotierbare Bindungen

7

Schwere Atome

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A peptide used as a diagnostic test for exocrine pancreatic function; after oral ingestion, pancreatic chymotrypsin cleaves the peptide to release para-aminobenzoic acid, which is measured in urine. It is not used as a therapeutic agent.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Bentiromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200368. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6957673. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.